Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000300 · ClinicalTrials.gov registry record · Phase 4
Feasibility Study of Take-Home LAAM Medication - 3
A Phase 4 study of Opioid-Related Disorders, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Study location
NCT00000300 is a Phase 4 study of Opioid-Related Disorders that has completed, run by University of California, Los Angeles. The trial reports 1 study location across 1 state.
The verdict
NCT00000300, a Phase 4 study of Opioid-Related Disorders, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1
- Study location
Study Summary
The purpose of this study is to test therapeutic benefits of take-home LAAM. (1) Do subjects with take-home LAAM availability show increased clinical responsibility over subjects without; (2) Do subjects with take-home LAAM attempt diversion when random recall and other diversion safeguards are used; (3) Does treatment response correlate with background or drug use variables at intake, discharge, or during treatment?
Conditions Studied
Interventions
- DRUG LAAM
Study Locations (1)
California
- Friends Research Institute - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Start Date | 1995-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000300
The ClinicalTrials.gov registry entry for NCT00000300 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which LAAM is the first listed.
NCT00000300 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00000300 about?
NCT00000300 is a clinical study titled "Feasibility Study of Take-Home LAAM Medication - 3". The purpose of this study is to test therapeutic benefits of take-home LAAM. (1) Do subjects with take-home LAAM availability show increased clinical responsibility over subjects without; (2) Do subjects with take-home LAAM attempt diversion when random recall and other diversion safeguards are used...
What is the current status of trial NCT00000300?
This trial is currently completed. It is a Phase 4 study. The study started on 1995-03.
What conditions does trial NCT00000300 study?
This clinical trial studies the following conditions: Opioid-Related Disorders.
What interventions are being tested in trial NCT00000300?
The interventions under investigation include: LAAM (DRUG).
Who is sponsoring clinical trial NCT00000300?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000300 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
COMPLETED · Phase 4
-
The Kentucky Viral Hepatitis Treatment Study
COMPLETED · Phase 4
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care
RECRUITING · NA
-
Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment
RECRUITING · NA
-
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.